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predictive Value of pretherapeutic 
Maximum standardized Uptake 
Value (suvmax) In Laryngeal and 
Hypopharyngeal Cancer
Jonas Werner1,5, Martin W. Hüllner2,5, Niels J. Rupp3,5, Alexander M. Huber1,5, 
Martina A. Broglie1,5, Gerhard F. Huber4,5 & Grégoire B. Morand1,5
the aim of the study was to evaluate whether pretherapeutic metabolic tumor parameters from 
18-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging could predict larynx 
preservation in laryngeal and hypopharyngeal cancer patients prior to primary chemoradiation. Tumor 
metabolic parameters [maximum standardized uptake value (sUVmax), metabolic tumor volume (MTV), 
and total lesion glycolysis (TLG)] were retrospectively assessed in a consecutive cohort of laryngeal 
and hypopharyngeal cancer patients undergoing primary (chemo-)radiation. Main outcome measures 
were larynx preservation and survival. The study included 97 patients with a median follow-up of 32 
months (IQR 20–54.5). For hypopharyngeal cancer, multivariable analysis showed that patients with 
a primary tumor’s sUVmax > 9.5 entailed a higher risk of undergoing salvage pharyngolaryngectomy 
after chemoradiation (HR = 8.64, 95% CI = 1.1–67.3, P = 0.040). In laryngeal cancer, SUVmax did not 
predict the need for salvage laryngectomy. The only predictor for larynx preservation in laryngeal 
cancer patients was T-classification at initial diagnosis (HR = 6.67, 95% CI = 0.82–53.9, P = 0.039). In 
conclusion, SUVmax of primary tumor could be used as a predictor of larynx preservation prior to primary 
chemoradiation in hypopharyngeal cancer patients. This information may be important for patient 
counseling, as high SUVmax was correlated with reduced probability of larynx preservation. However, in 
laryngeal cancer patients, SUVmax does not seem to be predictive of outcome.
In advanced stage III or IV laryngeal and hypopharyngeal squamous cell carcinoma, organ preservation strat-
egy involves primary chemoradiation as first-line therapy, reserving surgery such as laryngectomy or pharyn-
golaryngectomy for the salvage setting1,2. Primary upfront laryngectomy or pharyngolaryngectomy followed by 
adjuvant radiotherapy with or without concomitant chemotherapy, as needed, may be preferred in patients with 
surgically removable advanced stage carcinomas, as primary chemoradiation with salvage surgery may nega-
tively impact quality of life, functionality and survival3. Therefore, it is crucial to adequately select patients for 
either of the two strategies. Tumor response to induction chemotherapy has been used in seminal studies as a 
selection tool2. However, subsequent studies revealed the superiority of concurrent chemoradiation compared 
to induction chemotherapy followed by radiotherapy for laryngeal preservation, establishing a new standard of 
care4. Although a few clinical factors, such as gross cartilage infiltration, large tumor volume, and extensive nodal 
disease are already recognized as unfavorable factors for organ preservation strategy, it would be of interest to 
provide further tools for clinicians to base their therapeutic decision on5.
18-fluorodeoxyglucose positron emission tomography (FDG-PET) with computed tomography (CT) or 
magnetic resonance (MR) imaging has become a broadly accepted imaging tool in routine clinical oncology6. 
Adding FDG-PET to the staging process resulted in higher staging accuracy with improved nodal classifica-
tion7,8, superior detection of regional or distant metastases, and second primary cancers9,10. In addition, metabolic 
tumor parameters derived from FDG-PET have been suggested to serve as prognostic markers for the response 
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to chemoradiation11,12. Such metabolic parameters include maximum standardized uptake value (SUVmax), met-
abolic tumor volume (MTV), and total lesion glycolysis (TLG)13,14.
Tumors with a higher uptake of FDG have a more active tumor metabolism, which negatively correlates 
with tumor oxygenation through the Warburg effect15,16. Poor tumor oxygenation or tumor hypoxia is moreover 
associated with resistance to chemoradiation17,18. Consequently, we hypothesized that FDG-PET derived tumor 
metabolism markers, such as SUVmax, MTV, and TLG, can be used as predictors of response to chemoradiation. 
The aim of this study was therefore to examine whether different pretherapeutic FDG-PET parameters can pre-
dict organ preservation in laryngeal and hypopharyngeal cancer undergoing primary chemoradiation.
Materials and Methods
Study population. After Ethics Review Board approval by the Kantonale Ethikkomission Zürich (protocol 
number 2016–01799), all patients treated for laryngeal or hypopharyngeal squamous cell carcinoma between 
June 1st, 2007, and June 1st, 2017, at the Department of Otorhinolaryngology – Head and Neck Surgery of the 
Zurich University Hospital, Switzerland, were retrospectively assessed. All research was performed in accordance 
with relevant guidelines and regulations and informed consent of all enrolled patients was obtained. Inclusion cri-
teria were available pre- and posttherapeutic FDG-PET/CT or FDG-PET/MR images and treatment with curative 
intent. Patients treated with induction chemotherapy, patients that did not complete a course of radiotherapy of at 
least 60 Gray locally, and patients undergoing primary surgical treatment were excluded.
All patients were staged according to the Union Internationale Contre le Cancer (UICC), TNM staging for 
head and neck cancer, 7th edition, 201019. After full medical history, physical examination, triple endoscopy 
with biopsy, and imaging with FDG-PET, all patients were presented and discussed at the local interdisciplinary 
tumor board. Posttherapeutic FDG-PET/CT or -/MR images were obtained three months after completion of 
chemoradiation.
Detailed data on age, gender, tumor subsite, and risk factors including smoking, drinking habits, and human 
papilloma virus (HPV) status were obtained. Immunohistochemical expression of p16 or polymerase chain reac-
tion (PCR) for HPV were used to evaluate HPV status of tumor biopsy samples. Local and regional radiation 
dose, type and number of cycles of concomitant chemotherapy, time to salvage pharyngolaryngectomy and/or 
neck dissection, pathological tumor stage, number of nodes dissected, number of positive nodes, and follow-up 
time were assessed.
The study cohort was then divided into two groups according to tumor site, analyzing laryngeal and 
hypopharyngeal cancer separately. The primary outcome measure of the study was pharyngo-/laryngectomy-free 
survival. Secondary outcome measures included local and regional recurrence-free survival, distant 
metastasis-free survival, disease-specific survival, and overall survival.
FDG-PET/CT or -/MR image acquisition. Patients were injected with a standardized dose of 3.5 MBq of 
18-fluorodeoxyglucose (FDG) per kilogram body weight after fasting for at least four hours. All patients had a 
blood glucose level below 12 mmol/l before imaging. The patients were instructed to remain in lying or recumbent 
position and silent for 50–60 minutes to minimize muscular FDG uptake in the period between FDG injection 
and image acquisition. Patients were also kept warm prior to tracer injection and throughout the uptake period to 
diminish FDG accumulation in brown adipose tissue. All patients received either iodinated or gadolinium-based 
contrast medium. An integrated Discovery VCT PET/CT system (GE Healthcare, Waukesha, WI), a Discovery 
PET/CT 690 (GE Healthcare), or a hybrid PET/MRI system (Signa PET/MR, GE Healthcare) was used for image 
acquisition.
Tumor FDG metabolism. Selected parameters of tumor FDG metabolism were obtained under super-
vision of a board-certified nuclear physician and radiologist and comprised pre- und posttherapeutic SUVmax, 
TLG, and MTV of the primary tumor. Moreover, in patients with clinically positive nodal status, SUVmax of the 
most active metastatic lymph node was measured. SUVmax was calculated automatically using a standard formula 
[maximum activity in region of interest ÷ (injected dose × body weight)]. MTV was defined as the sum of the 
volume of voxels with an SUV exceeding a threshold of 42% of the SUVmax. TLG was defined mathematically as 
MTV × SUVmean. Correct analysis of FDG uptake was ensured through side-by-side reading of the corresponding 
CT or MR images of the tumor in the axial, coronal, and sagittal plane. Borders of regions of interest (ROI) were 
set by manual adjustment to exclude adjacent physiologic FDG-avid structures. A written report by a dually 
board-certified nuclear medicine physician/radiologist was available for pre- and posttherapeutic FDG-PET/CT 
or -/MR images.
Statistical analysis. For continuous variables, median, interquartile range (IQR), or standard deviation 
(SD) are given. To compare distribution among samples, the non-parametric Mann Whitney U test was used for 
two samples. Binary variables were associated in contingency tables using the two-tailed chi-squared test. Main 
outcome measures of the study were calculated using a multivariable Cox regression model. Results are expressed 
in hazard ratio (HR) with the 95% confidence interval provided (95% CI). Survival curves were built according to 
Kaplan-Meier and the log-rank test was used to compare factors. Receiver operating characteristic (ROC) curves 
were used to determine in which study group pretherapeutic SUVmax was a potential predictor of laryngectomy 
and to select the best cutoff value for SUVmax to predict high risk of laryngectomy. A P-value lower than 0.05 was 
considered to indicate statistical significance. Statistical analyses were performed using SPSS® 23.0.0.0 software 
(IBM®, Armonk, NY, USA).
Meeting presentation. This work was presented at the 2018 Swiss Society for Oto-rhino-laryngology Head 
and Neck Surgery, Spring Meeting, June 21st, 2018, Basel, Switzerland.
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Results
Patient and tumor characteristics. A total of 97 patients with advanced stage III or IV laryngeal or 
hypopharyngeal cancer were included in this study (Table 1). The median age at diagnosis was 64 years (IQR 
56–70). As expected, there was a clear male predominance with 85 (87.6%) male and 12 (12.4%) female patients. 
Forty patients (41.2%) had squamous cell carcinomas of the larynx and 57 patients (58.8%) of the hypopharynx. 
Most patients (58.8%) had cT3-cT4 tumors in comparison to 41.2% of patients with cT1-cT2 tumors, including 
glottic carcinomas. Clinical nodal status was positive in 61 patients (62.9%), of which 40 (41.3%) were staged with 
cN1-cN2b and 21 (21.6%) with cN2c-cN3 categories.
The median pretherapeutic SUVmax was 10.4 (IQR 7.4–15.7) for the whole cohort, while the median TLG 
was 34696 (IQR 18160–75166), and median MTV was 6.1 cm3 (IQR 3.6–8.7 cm3). Median follow-up time for all 
patients was 32 months (IQR 20–54.5).
Treatment characteristics. Patients received either intensity-modulated radiotherapy (IMRT) or volumet-
ric modulated arc therapy (VMAT) with a mean total dose of 70 Gray locally (SD 1.65) and 54 Gray (SD 0.83) 
regionally. Seventy-four patients (76.3%) received concomitant chemotherapy. 63.5% of chemotherapies were 
based on cisplatin with a median of five cycles (SD 0.97), while 17.6% consisted of cetuximab with a median of 
four cycles (SD 1.81). Fourteen patients (18.9%) received both cisplatin and cetuximab, either based on the study 
protocol of a clinical trial20 or because the therapy was changed to cetuximab due to adverse effects of cisplatin.
Twenty-three patients (23.7%) underwent salvage surgery. Of those, 60.9% had hypopharyngeal cancer and 
underwent pharyngolaryngectomy and 39.1% had laryngeal cancer with salvage laryngectomy. Median time to 
pharyngo-/laryngectomy was 13.5 months (IQR 8.8–16.3). Frozen sections were used intraoperatively to assure 
free margins of the surgical resection specimen and all patients had negative margins upon final pathology (R0).
Neck dissection was performed either on its own or combined with pharyngo-/laryngectomy on 35 patients 
(36.1%) after a median time of 7 months (IQR 6–14). Eight of these patients (22.8%) had laryngeal cancer in 
comparison to 27 hypopharyngeal carcinomas (77.2%). Twenty of 35 patients (57.1%) had positive nodal disease 
(ypN+) with a mean of 2.3 positive lymph nodes (SD 2.59).
Variable
All patients
No. of patients = 97
Hypopharynx (H)
No. of patients = 57
Larynx (L)




Years Median (Q25-75) 64 (56–70.5) 64 (58–71) 62.5 (54–70)
Gender 0.199
Male n (%) 85 (87.6%) 52 (91.2%) 33 (82.5%)
Female n (%) 12 (12.4%) 5 (8.8%) 7 (17.5%)
Smoking  Present (%) 94 (96.9%) 55 (96.5%) 39 (97.5%) 0.778
Absent (%) 3 (3.1%) 2 (3.5%) 1 (2.5%)
Pack years Median (Q25-75) 40 (30–60) 40 (20–60) 50 (40–80) 0.014*
Alcohol abuse
 Present (%) 49 (50.5%) 32 (56.1%) 17 (42.5%) 0.186
 Absent (%) 48 (49.5%) 25 (43.9%) 23 (57.5%)
p16/ HPV PCR
Positive 8 (8.3%) 6 (10.5%) 2 (5%) 0.681
Negative 37 (38.1%) 25 (43.9%) 12 (30%)
n/a 52 (53.6%) 26 (45.6%) 26 (65%)
PET imaging
SUVmax primary tumor Median (Q25-75) 10.4 (7.4–15.7) 12.3 (9.2–15.3) 8.8 (6.7–16.6) 0.062
TLG primary  tumor Median (Q25-75) 34696 (18160–75166) 42926 (21467–77672)
29060 (15555–
55644) 0.054
MTV primary tumor (cm3) Median (Q25-75) 6.1 (3.6–8.7) 6.1 (3.6–9.7) 5.9 (3.5–8.2) 0.393
SUVmax nodal (cN+) Median (Q25-75) 9.7 (7.3–11.8) 10.8 (7.5–12.3) 8 (6.8–10) 0.041*
Pharyngo-/Laryngectomy
Yes (%) 23 (23.7%) 14 (24.6%) 9 (22.5%) 0.814
No (%) 74 (76.3%) 43 (75.4%) 31 (77.5%)
T-classification 0.99
T1-T2 n (%) 40 (41.2%) 24 (42.1%) 16 (40%)
T3-T4 n (%) 57 (58.8%) 33 (57.9%) 24 (60%)
N-classification <0.001*
N0 n (%) 36 (37.1%) 10 (17.5%) 26 (65%)
N1 n (%) 11 (11.3%) 8 (14%) 3 (7.5%)
N2a-b n (%) 29 (30%) 23 (40.4%) 6 (15%)
N2c-N3 n (%) 21 (21.6%) 16 (28.1%) 5 (12.5%)
Table 1. Patient Demographics and Clinical Characteristics. aMann-Whitney U Test for continuous variables, 
2-sided Pearson Chi-Squared Test for categorical variables. SUVmax: maximum standard uptake value. TLG: 
total lesion glycolysis. MTV: metabolic tumor volume. P value for null hypothesis; *statistically significant.
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Primary Outcome Analysis: Organ Preservation. Various cutoff values for FDG uptake parameters 
were tested for the different study cohorts. Using receiver operating characteristic (ROC) curves, it was deter-
mined that pretherapeutic SUVmax was predictive of laryngectomy for hypopharyngeal cancer patients but not 
for laryngeal cancer patients (Fig. 1, Panel A–C). For hypopharyngeal cancer patients, the best potential cutoff 
value for pretherapeutic SUVmax was determined to be 9.5 (Fig. 1, Panel B, sensitivity 92.9%, specificity 37.2%, 
P = 0.016). Factors possibly predicting organ preservation were analyzed separately between hypopharyngeal 
(Table 2) and laryngeal cancer patients (Table 3), using a univariable and multivariable Cox regression model.
In hypopharyngeal cancer, univariable analysis showed that pretherapeutic SUVmax ≥ 9.5 and T3/4 classifi-
cation were predictors for salvage pharyngolaryngectomy. In multivariable analysis, the only independent pre-
dictor of salvage laryngopharyngectomy was a pretherapeutic SUVmax of the primary tumor ≥ 9.5 (HR = 8.64, 
95% CI = 1.1–67.3, P = 0.040). Comparative Kaplan-Meier survival analysis showed a worse laryngectomy-free 
survival in patients with pretherapeutic SUVmax ≥ 9.5 (Fig. 2A, Log rank test, P = 0.010).
The risk of salvage pharyngolaryngectomy according to pretherapeutic SUVmax of the primary tumor was also 
evaluated in ordinal fashion. For patients with pretherapeutic SUVmax < 9.5, risk of laryngectomy was low. The 
Figure 1. Receiver operating characteristic (ROC) curve analysis of laryngectomy prediction according to 
pretherapeutic SUVmax of primary tumor. (A) ROC curve for all patients showing lack of significant correlation 
(area under the curve (AUC) = 0.595 (95% CI = 0.460–0.730, P = 0.171). (B) ROC in hypopharyngeal 
cancer patients only. The area under the ROC curve was 0.715 (95% CI = 0.562–0.868, P = 0.016) and 9.5 
was determined as best potential cutoff value for comparison. The sensitivity and specificity for SUVmax = 9.5 
were 92.9% and 37.2%, respectively. (C) ROC curve in laryngeal cancer patients showing lack of significant 
correlation (AUC = 0.455 (95% CI = 0.241–0.699, P = 0.686).
Variable
Univariable analysis Multivariable analysis
HR 95% CI P value HR 95% CI P value
Gender
Male vs. Female 1.37 0.18–10.5 0.760
Age
≥ 70 vs. <70 years 0.58 0.19–1.72 0.342
T-classification
T3 + T4 vs. T1 + T2 3.77 1.05–13.6 0.028* 3.49 0.96–12.6 0.057
N-classification
N2 + N3 vs. N0 + N1 2.69 0.60–12.1 0.194
Alcohol abuse
Present vs. absent 0.43 0.14–1.30 0.139
Smoking
Present vs. absent 0.56 0.73–4.31 0.577
SUVmax primary tumor  
≥9.5 vs. <9.5 8.89 1.12–70.1 0.013* 8.64 1.10–67.3 0.040*
TLG primary tumor  
≥20k vs. <20k 5.53 0.71–42.9 0.102
MTV primary tumor  
≥6 vs. <6 cm3 1.71 0.59–4.99 0.318
Table 2. Cox regression analysis for pharyngolaryngectomy-free survival for hypopharyngeal cancer patients 
(No. of patients = 57). HR: hazard ratio. 95% CI: 95% confidence interval. SUVmax: maximum standard uptake 
value. TLG: total lesion glycolysis. MTV: metabolic tumor volume. P value for null hypothesis; *statistically 
significant.
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risk of laryngectomy increased with a higher pretherapeutic SUVmax in an almost linear manner, as depicted in 
Fig. 3.
In laryngeal cancer, the only predictor of laryngeal preservation was T-classification (HR = 6.67, CI = 0.82–
53.9, P = 0.039) in univariable analysis. Gender, age, N-classification, smoking, alcohol abuse, and metabolic 
tumor parameters (pretherapeutic SUVmax, MTV, TLG) were not predictors of organ preservation (Table 3, each 
P > 0.05).
As expected, a low posttherapeutic SUVmax (<3.0) was also predictive of organ preservation in laryngeal and 
hypopharyngeal cancer (Log-rank test P = 0.001, not shown)
Secondary outcome analysis: survival. The cumulative distant metastasis-free survival at 60 months was 
69%. A majority of patients (58.3%) presented with pulmonary metastases. The only factor significantly predictive 
of distant metastases was nodal stage at diagnosis (Fig. 4, log-rank test, P = 0.004). The cumulative disease-specific 
survival at 60 months was 61%, with most events occurring within the first three years of follow-up. The cumula-
tive overall survival at 60 months was 49%.
Pretherapeutic SUVmax of the primary tumor was not predictive of regional recurrence-free survival, dis-
tant metastasis-free survival, disease-specific survival, and/or overall survival (not shown, log-rank test, each 
P > 0.05).
Posttherapeutic SUVmax of the primary tumor was predictive of distant metastasis-free survival, 
disease-specific survival (log-rank test, P = 0.046 and P = 0.021, respectively) but not of regional recurrence-free 
and overall survival (log-rank test, each P > 0.05).
Variable
Univariable analysis
HR 95% CI P value
Gender
Male vs. Female 30.9 0.04–219 0.305
Age
≥ 70 vs. <70 years 29.1 0.28–296 0.340
T-classification
T3 + T4 vs. T1 + T2 6.67 1.12–53.9 0.039*
N-classification
N2 + N3 vs. N0 + N1 0.49 0.06–3.98 0.508
Alcohol abuse
Present vs. absent 1.09 0.29–4.07 0.895
Smoking
Present vs. absent 20.45 0.01–734 0.876
SUVmax primary tumor  
≥9.5 vs. <9.5 0.56 0.13–2.26 0.407
TLG primary tumor  
≥20 K vs. <20 K 0.79 0.19–3.25 0.753
MTV primary tumor  
≥6 vs. <6 cm3 0.73 0.19–2.73 0.641
Table 3. Univariable analysis for laryngectomy-free survival for laryngeal cancer patients (No. of patients = 40). 
HR: hazard ratio. 95% CI: 95% confidence interval. SUVmax: maximum standard uptake value. TLG: total 
lesion glycolysis. MTV: metabolic tumor volume. P value for null hypothesis; *statistically significant.
Figure 2. Kaplan-Meier curves showing laryngectomy-free survival. (A) High SUVmax predicted poorer 
laryngectomy-free survival in hypopharyngeal cancer patients (Log rank test, P = 0.010). (B) In laryngeal 
cancer patients, laryngectomy-free survival was predicted by T-category before chemoradiation.
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Discussion
This study evaluates whether pretherapeutic metabolic parameters of laryngeal and hypopharyngeal cancer 
patients can predict tumor response to chemoradiation. Pretherapeutic SUVmax of the primary tumor was a pre-
dictor of laryngeal preservation before chemoradiation in hypopharyngeal cancer but did not seem to be predic-
tive of organ preservation in laryngeal cancer.
The primary goal of our study was to identify pretherapeutically available markers to assist in clinical decision mak-
ing, choosing between primary chemoradiation and primary surgery followed by adjuvant radiotherapy, as needed.
We also analyzed posttherapeutic metabolic parameters and showed, in accordance with previously published 
literature21,22, that a high posttherapeutic SUVmax is indicative of poor metabolic response to chemoradiation and 
predictive of the need for salvage laryngectomy and worse distant metastasis-free and disease-specific survival.
Tumor hypoxia is known to adversely affect tumor response to radiotherapy17, attributed to a decrease of 
radiation-induced DNA damage under reduced oxygen conditions23. Hypoxic microenvironment within tum-
ors alters cellular metabolism and triggers a myriad of molecular responses including upregulation of hypoxia 
Figure 3. Frequency curve showing risk of laryngectomy according to SUVmax of primary tumor arranged in 
ordinal fashion. For patients with low SUVmax (<9.5), risk of laryngectomy was low. The risk of laryngectomy 
increased with higher SUVmax in an almost linear manner.
Figure 4. Kaplan-Meier analysis showing distant metastasis-free survival in hypopharyngeal and laryngeal 
cancer patients according to nodal status (Log rank test, P = 0.004).
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inducible factors (HIFs)24. HIFs in turn promote transcription activation with upregulation of SNAIL and TWIST 
signaling pathways, resulting in activation of epithelial to mesenchymal transition (EMT)25,26. Hypoxia and HIFs 
also induce expression of GLUT1 to provide the cell with sufficient energy through increased glucose uptake, 
including also FDG27. Our hypothesis was therefore that FDG-PET metabolic parameters, such as SUVmax, could 
be used as surrogate markers of tumor hypoxia and poor prognosis. This hypothesis could be confirmed in 
hypopharyngeal (as Fig. 5 shows in an exemplary way) but not in laryngeal cancer. For the latter, T-classification 
at diagnosis was predictive of laryngeal preservation. Although we do not know the reason for this discrepancy, 
one factor might be the unassessed confounding effect of cartilage infiltration, which is a known predictor of poor 
response to chemoradiation, that may, however, be insufficiently addressed by the TNM classification19. Of impor-
tance, T-classification should not be underscored in hypopharyngeal cancer patients, as T3/T4 tumors tended 
towards poorer laryngectomy-free survival. The two cancer entities also differ in their tendency towards nodal 
metastasis28. Hypopharyngeal carcinomas are generally considered to develop nodal metastases earlier and more 
frequently compared to laryngeal cancer29,30. Comparing advanced stage hypopharyngeal and laryngeal carcino-
mas, patients with hypopharyngeal cancer are hence more likely to present with advanced nodal disease while 
those with cancer of the larynx are more likely to have a larger primary tumor to be categorized as advanced stage 
(Fig. 6 shows an example of a stage III (cT3 cN0 cM0) laryngeal cancer). This may feature another confounding 
factor in the analysis of tumor response to radiotherapy, although we did adjust for it in our multivariable analysis.
To the best of our knowledge, our study is the first to show that pretherapeutic SUVmax could help clinicians 
in decision-making to adequately select hypopharyngeal cancer patients suitable for organ preservation therapy. 
Nevertheless, previous studies have already suggested the potential of FDG-PET parameters in the prediction 
of organ preservation. Park et al.14 retrospectively analyzed the prognostic value of hypopharyngeal and laryn-
geal cancer metabolism in FDG-PET imaging before treatment. They identified MTV as an independent prog-
nostic factor for both locoregional control (HR = 3.141, 95% CI = 1.175–8.399, P = 0.018) and overall survival 
(HR = 3.758, 95% CI = 1.415–9.982, P = 0.008). However, they did not separate upfront surgery with adjuvant radi-
o(chemo)therapy from primary chemoradiation with salvage surgery, when needed. In their analysis of DeLOS-II 
trial, a German multicenter randomized phase II trial investigating functional organ preservation in patients with 
laryngeal and hypopharyngeal cancer receiving induction chemotherapy with or without cetuximab followed by 
radiotherapy, Wichmann et al.5 proposed a score facilitating decision-making between laryngectomy and organ 
Figure 5. Representative axial fusion PET/CT images demonstrating two hypopharyngeal cancer patients. (A) 
This patient presented with a high SUVmax at diagnosis and underwent salvage laryngopharyngectomy. (B) This 
patient’s tumor exhibits a low SUVmax and responded completely to chemoradiation.
Figure 6. Example of a cT3 glottic carcinoma of the larynx in a 78-year-old patient. The tumor displays a 
SUVmax of 10.4, an MTV of 7 cm³, and a TLG of 45’830. (A) Frontal view of PET image. (B) Axial view of fused 
PET/CT image. (C) Sagittal fusion PET/CT image of the tumor.
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preservation strategy based on the tumor’s early response to induction chemotherapy. Their score, identifying 
patients benefitting from larynx preservation strategies and those unsuitable for it, included the number of positive 
nodes, residual tumor volume, and a ratio of residual SUVmax to SUVmean above 1.51 after induction chemotherapy5.
In our study, SUVmax was the one FDG-PET parameter with the best predictive value regarding organ preser-
vation. Although other studies have recently emphasized on volumetric FDG-PET parameters such as MTV or 
TLG13,31, SUVmax has the advantage to be a standardized and easily applicable measure with the highest availabil-
ity32. In clinical practice, it is better reproducible and less subject to variation due to different definitions of the 
region of interest or due to spill-over of adjacent FDG-avid structures33.
Based on our statistical analysis, we propose an SUVmax cutoff of 9.5 to distinguish between hypopharyngeal 
tumors with high and low risk of salvage pharyngolaryngectomy. In a previous study on oral cancer, our group 
already reported an SUVmax cutoff of 9.534. Other studies assessing the association between SUVmax and survival 
reported cutoff values between 8.0 and 9.0 to identify head and neck carcinomas at risk of shorter disease-free 
and overall survival35–37.
Although organ preservation is of great importance for patients from a psychological, social, and functional 
point of view, our study shows that hypopharyngeal carcinomas with high SUVmax are at greater risk of treatment 
failure and should be considered for upfront surgery followed by adjuvant radio(chemo)therapy. With the inten-
sification of nonoperative treatment approaches, an increasing number of patients are experiencing long-term 
swallowing impairments and functional deficiencies38. These late toxic effects are more common following pri-
mary chemoradiation in comparison to upfront surgery with postoperative radiotherapy38,39. Tschiesner et al.40 
analyzed the functional outcome in patients with advanced head and neck cancer comparing upfront surgery 
with primary chemoradiation in a cross-sectional, multi-institutional study. They reported no significant differ-
ence between the two groups regarding most aspects of functional outcome. However, body functions, includ-
ing swallowing and weight maintenance, as well as activities and participations, including social relationships, 
employment, and economic self-sufficiency, were observed to be more problematic in patients receiving initial 
chemoradiation. Moreover, Jang et al.41 compared oncological and functional outcomes between initial surgical 
versus non-surgical treatments for hypopharyngeal cancer in 332 patients. Their data revealed similar oncolog-
ical outcome and showed even better verbal communication outcomes in advanced-stage hypopharyngeal can-
cer patients receiving initial chemoradiation. Nevertheless, more patients treated with primary chemoradiation 
required multiple surgical interventions in the process. This may be explained through a reported failure rate of 
organ preservation of approximately 46% and also because a significant proportion of survivors with a preserved 
organ required tracheostomy due to a dysfunctional larynx41,42.
Our study goal was to assess tumor response to chemoradiation according to SUVmax of the primary tumor 
but not to assess how the larynx reacted to chemoradiation. Our study might therefore overestimate actuarial 
organ preservation, as patients who formally achieved organ preservation were assessed as such, regardless of 
the function of their larynx after chemoradiation. Another limitation of our study is its retrospective design. 
Furthermore, PET scans were acquired on different scanners, albeit the SUVmax is a standardized measure. In 
addition, the number of patients was relatively low in our study. Differences among groups were, however, size-
able enough to be detected and to avoid beta error43. Lastly, owing to the small size of the study population, a 
sub-analysis depending on HPV status was not performed. In contrast to oropharyngeal cancer, the percentage 
of HPV-positive tumors of the hypopharynx or larynx is considerably lower and therefore less confounding. 
Moreover, there is no evidence that HPV-positive hypopharyngeal or laryngeal cancers have a comparable better 
prognosis as it is the case for oropharyngeal tumors.
In conclusion, SUVmax of primary tumor could be used as a predictor of laryngeal preservation before chemo-
radiation in hypopharyngeal cancer. This information may be of great impact in patient counseling, as SUVmax 
was inversely correlated with the chance of larynx preservation. SUVmax, however, does not seem to be predictive 
of outcome in laryngeal cancer.
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